Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 09, 2023 16:01 ET
|
Erasca, Inc.
First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents,...
Erasca to Present at Upcoming Investor Conferences in November
November 08, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present at the Cantor Global Healthcare Conference
September 19, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
August 29, 2023 08:00 ET
|
Erasca, Inc.
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in...
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 10, 2023 16:01 ET
|
Erasca, Inc.
Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple...
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
June 22, 2023 16:01 ET
|
Erasca, Inc.
ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June 22, 2023 ...
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
June 05, 2023 16:01 ET
|
Erasca, Inc.
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK...
Erasca to Present at Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
May 31, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...